Company / Cash & Equivalents
Elevance Health Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$9.5B
FY2025
5-year range
$4.9B / $9.5B
FY2021-FY2025
Trend
+14.5%
vs FY2024
Sector context
#4 of 148
Health Care
What the data says
Among 148 Health Care companies, Elevance Health is in the top 3% for cash & equivalents. Cash & Equivalents has fluctuated over the past 10 years, ranging from $3.6B in FY2017 to $9.5B in FY2025.
Based on SEC 10-K filings.
$9.5B in FY2025 with a 5-year CAGR of +10.6%. Top quartile in the Health Care sector.
Improved from $6.5B to $9.5B over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +8.7%
- 5-Year CAGR
- +10.6%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 148This company $9.5B Sector average $1.2B
▼
+706.5% above sector average
Key checks
Key Insights
- 5-year CAGR of +10.6%, indicating consistent growth.
- In FY2025, cash & equivalents increased 14.5% year-over-year.
- Ranks #4 out of 148 companies in the Health Care sector.
- Lowest cash & equivalents in the period was in FY2017.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.5B | +14.5% |
| FY2024 | $8.3B | +27.0% |
| FY2023 | $6.5B | -11.7% |
| FY2022 | $7.4B | +51.4% |
| FY2021 | $4.9B | -15.0% |
| FY2020 | $5.7B | +16.3% |
| FY2019 | $4.9B | +25.5% |
| FY2018 | $3.9B | +9.0% |
| FY2017 | $3.6B | -11.4% |
| FY2016 | $4.1B | +92.9% |
As of FY2025 · SEC 10-K · Updated Jul 4, 2026